Editas Medicine (EDIT) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Editas Medicine (EDIT) has outperformed ProKidney (PROK) over the past year, losing 30.0% versus a loss of 47.0%. Over five years, PROK leads with a -84.1% price change compared with -92.8% for EDIT. ProKidney is the larger company by market cap ($626.7 million vs $422.3 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | PROK |
|---|---|---|
| Share price | $2.75 | $1.57 |
| Market cap | $422.35M | $626.72M |
| 1-day change | +0.73% | -1.88% |
| YTD return | +34.15% | -29.91% |
| 1-year return | -30.03% | -46.96% |
| 5-year return | -92.77% | -84.09% |
| EPS (TTM) | $-0.68 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $3.48 |
| 52-week low | $1.66 | $1.30 |
| Distance from 52-week high | -36.49% | -54.89% |
| Average volume | 2.48M | 1.31M |
| Shares outstanding | 153.58M | 208.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed PROK by 16.9 percentage points over the past year.
EDIT vs PROK FAQ
Which is bigger, Editas Medicine or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $626.72M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or PROK?
EDIT returned -30.03% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.